Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
A recent observational study has raised concerns about a potential link between the GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts.
最近的觀察性研究引發了人們對GLP-1藥物Ozempic和Wegovy可能與自殺念頭增加的潛在聯繫的擔憂。
The study, published Tuesday in JAMA Network Open, analyzed data from the World Health Organization's database and reported a higher incidence of suicidal ideation associated with semaglutide, the active ingredient in Novo Nordisk A/S' (NYSE:NVO) Wegovy and Ozempic, compared to other medications.
《JAMA通訊網絡》週二發表的一項研究分析了世界衛生組織數據庫中的數據，並報告稱與Novo Nordisk A/S（紐交所：NVO）Wegovy和Ozempic的有效成分Semaglutide相比，在其他藥物中，與自殺念頭相關的自殺意向發生率更高。
Also Read: Novo Nordisk's Ozempic And Wegovy Helps Lose Weight, Not One's Mind: US Study Finds No Increased Suicidal Thoughts Risk.
此外閱讀：Novo Nordisk的Ozempic和Wegovy可幫助減重，但不會讓你失去理智：美國研究發現，沒有增加自殺念頭的風險。
The researchers found a greater rate of reports of suicidal thoughts specifically related to semaglutide when compared to other diabetes and obesity treatments like AstraZeneca Plc's (NASDAQ:AZN) Farxiga (dapagliflozin), metformin, and orlistat.
研究人員發現在與其他糖尿病和肥胖症治療方法，如阿斯利康公司（納斯達克：AZN）的法格西古丁（dapagliflozin）、二甲雙胍和奧利司他相比，與塞馬格列肽有關的自殺念頭的報告比例更高。
However, the overall rate of such thoughts was small, comprising only 0.3% of all adverse reactions for semaglutide when compared to 30,527 adverse reactions.
然而，所有關於其中心理健康問題的報告，只佔塞馬格列肽的所有不良反應的0.3％。
Notably, the study did not find an increased rate of more severe behaviors, such as suicide attempts or self-injury, linked to semaglutide.
值得注意的是，該研究未發現與塞馬格列肽有關的更嚴重行爲（如自殺企圖或自傷）的增加率。
Additionally, no higher rates of suicidal thoughts were associated with liraglutide, another GLP-1 drug from Novo Nordisk.
此外，來自諾和諾德的另一種GLP-1藥物利拉魯肽也沒有出現更高的自殺念頭發生率。
The researchers add that this is the first report examining the link between semaglutide and suicidal thoughts using this database.
研究人員補充說，這是第一篇使用該數據庫檢查塞馬格列肽和自殺念頭之間聯繫的報告。
The sensitivity analyses showed that the association remained significant when antidepressants or benzodiazepines were co-reported, suggesting a higher risk of suicidal ideation in patients with anxiety and depression taking semaglutide.
敏感性分析顯示，當抗抑鬱劑或苯二氮平共同報告時，聯合使用塞馬格列肽的焦慮和抑鬱患者存在更高的自殺意向風險，這個關聯關係仍然具有顯著性。
However, when excluding cases with co-reported antidepressants, the association was not significant, while it persisted when benzodiazepines were excluded.
但是，當排除共同報告抗抑鬱劑的病例時，這個關聯關係不再顯著，而在排除苯二氮平時，這個關係仍然存在。
This suggests a possible interaction between semaglutide and underlying psychiatric conditions that warrant further investigation.
這表明，塞馬格列肽和潛在精神疾病之間可能存在交互作用，需要進一步研究。
Although the European Medicines Agency has not recommended updating the product information, the researchers propose adding a precaution for use in patients with psychiatric disorders to the semaglutide label.
儘管歐洲藥品管理局未建議更新產品信息，研究人員建議在塞馬格列肽標籤中添加用於治療精神障礙患者的預防措施。
Notably, the FDA label for semaglutide for obesity already advises monitoring for depression or suicidal thoughts.
值得注意的是，用於肥胖症的塞馬格列肽的FDA標籤已經建議監測抑鬱症或自殺念頭。
Price Action: NVO stock is down 0.21% at $134.96 at the last check on Tuesday.
價格走勢：週二最近一次檢查時，NVO股票下跌了0.21％，報134.96美元。
- InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday.
- InMed Pharmaceuticals推進口服候選藥物治療阿爾茨海默病，週二股價大漲。
Image via Shutterstock
圖片來自shutterstock。